|
LO-1
|
Will be able to explain the brain. |
|
LO-2
|
Will be able to define the spinal cord. |
|
LO-3
|
Will be able to explain general concepts related to the physiology of the central nervous system. |
|
LO-4
|
Will be able to define the amine-based neuromediators of the central nervous system. |
|
LO-5
|
Will explain the amino acid-based neurotransmitters of the central nervous system. |
|
LO-6
|
Will explain the peptide-based neurotransmitters of the central nervous system. |
|
LO-7
|
Will explain sensory receptors and neuronal circuits in information processing. |
|
LO-8
|
Will explain the general organization of somatic sensations, including touch and proprioception. |
|
LO-9
|
Will explain somatic sensations: pain, headache, and thermal sensations. |
|
LO-10
|
Will explain the motor functions of the spinal cord: spinal reflexes. |
|
LO-11
|
Will explain the control of motor functions by the cortex and brainstem. |
|
LO-12
|
Will explain the contributions of the cerebellum and basal ganglia to general motor control. |
|
LO-13
|
Will explain the mental functions of the brain cortex. |
|
LO-14
|
Will explain the brain mechanisms related to behavior and motivation – the limbic system and hypothalamus. |
|
LO-15
|
Will explain the brain's activity states – sleep, brain waves, epilepsy, psychoses, and dementia. |
|
LO-16
|
Will explain brain blood flow, cerebrospinal fluid, and brain metabolism. |
|
LO-17
|
Will define skeletal muscle excitation: neuromuscular transmission and excitation-contraction coupling. |
|
LO-18
|
Will be able to explain skeletal muscle contraction. |
|
LO-19
|
Will be able to regulate body temperature and define fever. |
|
LO-20
|
Will be able to discuss the regulation of nutrition. |
|
LO-21
|
Will be able to explain leukocytes, granulocytes, the monocyte-macrophage system, and inflammation. |
|
LO-22
|
Will be able to define the drugs used in mood disorders. |
|
LO-23
|
Will be able to define the drugs used in the treatment of psychotic disorders. |
|
LO-24
|
Will be able to define opioid analgesics. |
|
LO-25
|
Will be able to define non-steroidal anti-inflammatory drugs (NSAIDs). |
|
LO-26
|
Will be able to define the drugs used in the treatment of Parkinson's disease and other movement disorders. |
|
LO-27
|
Will be able to define the drugs used in the treatment of Alzheimer's disease. |
|
LO-28
|
Will be able to define general anesthetics. |
|
LO-29
|
Will be able to define local anesthetics. |
|
LO-30
|
Will be able to define skeletal muscle relaxants. |
|
LO-31
|
Will be able to define hypnotic-sedative drugs. |
|
LO-32
|
Will be able to define anxiolytic drugs. |
|
LO-33
|
Will be able to define antiepileptic drugs. |
|
LO-34
|
Will be able to explain the adverse effects induced by drugs used in mood disorders. |
|
LO-35
|
Will be able to explain the adverse effects induced by drugs used in the treatment of psychotic disorders. |
|
LO-36
|
Will be able to explain the adverse effects induced by opioid analgesics. |
|
LO-37
|
Will be able to explain the adverse effects induced by non-steroidal anti-inflammatory drugs (NSAIDs). |
|
LO-38
|
Will be able to explain the adverse effects induced by the drugs used in the treatment of Parkinson's disease and other movement disorders. |
|
LO-39
|
Will be able to explain the adverse effects induced by the drugs used in the treatment of Alzheimer's disease. |
|
LO-40
|
Will be able to explain the adverse effects induced by general anesthetics. |
|
LO-41
|
Will be able to explain the adverse effects induced by local anesthetics. |
|
LO-42
|
Will be able to explain the adverse effects induced by skeletal muscle relaxants. |
|
LO-43
|
Will be able to explain the adverse effects induced by hypnotic-sedative drugs. |